Dipna Pharmachem Ltd
BSE:543594
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
D
|
Dipna Pharmachem Ltd
BSE:543594
|
306.3m INR |
Loading...
|
|
| US |
|
Mckesson Corp
NYSE:MCK
|
115.3B USD |
Loading...
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
68.5B USD |
Loading...
|
|
| US |
|
Cencora Inc
NYSE:COR
|
70B USD |
Loading...
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
51.9B USD |
Loading...
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
34.8B AUD |
Loading...
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.3B USD |
Loading...
|
|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.8B CNY |
Loading...
|
|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
63.8B CNY |
Loading...
|
|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
Loading...
|
|
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
66.1B HKD |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
Dipna Pharmachem Ltd
Glance View
Dipna Pharmaceuticals Ltd. engages in the trading and distribution of pharmaceutical raw material and chemical formulation products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2022-09-08. The firm's products include albendazole, ambroxol HCL, amisulpride IP/BP, amoxicillin aripiprazole IP, artemether, azithromycin, cefixime, carbamezapin, calcium gluconate IP, cefadroxyl monohydrate IP/BP/EP cephalexin, clindamycin phosphate IP/BP/USP, clotrimazole, cetrimide powder, chlorhexidine base, chlorhexidine gluconate 20% solution, chlorhexidine hydrochloride, chlorhexidine acetate, dapoxetine HCL, dextromethorphan hydrobromic (DMR), diclofenac potassium, diclofenac sodium, dried alluminiumhydroxide IP, ferric ammounium citrate IP, ferrous ascorbate, folic acid IP, guaiphenesin IP, griseofulvin IP /BP, hydrocortisone acetate, ibuprofen IP, levofloxacin, lumefantrine, lidocaine base, lidocaine hydrochloride, lornoxicam, metronidazole plain/benzoate and mefenamic acid IP.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Dipna Pharmachem Ltd is 0.8%, which is above its 3-year median of 0.7%.
Over the last 2 years, Dipna Pharmachem Ltd’s Net Margin has decreased from 0.8% to 0.8%. During this period, it reached a low of 0.5% on Sep 30, 2024 and a high of 0.8% on Aug 30, 2023.
